INNV InnovAge Holding Corp.

Nasdaq Services-Health Services DE CIK: 0001834376
AI RATING
SELL
78% Confidence

Investment Thesis

InnovAge demonstrates strong 11.8% revenue growth and positive free cash flow of $33.4M, but the company is unprofitable with negative operating and net margins (-1.0% and -1.5%), and profitability is deteriorating with diluted EPS declining 37.5% YoY. The combination of worsening profitability despite revenue growth, tight liquidity (1.03x current ratio), and negative ROE/ROA raises concerns about business model sustainability and management's ability to convert revenue growth into profits.

Strengths

  • + Strong revenue growth of 11.8% YoY ($727.8M) demonstrating market expansion
  • + Positive free cash flow of $33.4M despite operating losses, indicating underlying operational cash generation
  • + Conservative debt structure with low leverage (Debt/Equity 0.24x) and manageable debt burden
  • + Adequate cash reserves of $95.5M providing operational liquidity buffer

Risks

  • ! Operating unprofitability: negative operating income (-$7.5M) and net income (-$10.8M) indicate structural margin pressures
  • ! Deteriorating profitability trend: diluted EPS declined 37.5% YoY, suggesting loss expansion relative to revenue
  • ! Thin liquidity position with current ratio of 1.03x provides minimal cushion for operational disruptions or unexpected cash needs
  • ! Negative return metrics (ROE -4.7%, ROA -2.0%) indicate poor asset efficiency and shareholder value destruction

Key Metrics to Watch

Financial Metrics

Revenue
727.8M
Net Income
-10.8M
EPS (Diluted)
$-0.08
Free Cash Flow
33.4M
Total Assets
547.4M
Cash
95.5M

Profitability Ratios

Gross Margin 22.7%
Operating Margin -1.0%
Net Margin -1.5%
ROE -4.7%
ROA -2.0%
FCF Margin 4.6%

Balance Sheet & Liquidity

Current Ratio
1.03x
Quick Ratio
1.03x
Debt/Equity
0.24x
Debt/Assets
52.7%
Interest Coverage
-2.87x
Long-term Debt
55.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-09T08:26:06.784775 | Data as of: 2026-03-31 | Powered by Claude AI